In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

Inotek Pharmaceuticals Corporation. Trade Record

NASDAQ:ITEK Inotek Pharmaceuticals Corporation stock gains 71.27% Exit Oct 16, 2017 a Trade Record by priceseries

Trade Chart
Trade Chart ITEK Sep 20, 2017, priceSeries
About Inotek Pharmaceuticals Corporation

Inotek Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for glaucoma and other diseases of the eye in the United States. The company's lead product candidate includes Trabodenoson, a monotherapy that is in Phase III clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a fixed-dose combination prostaglandin analogue, which has completed the Phase II clinical trials for IOP-lowering in patients who have previously had inadequate response to latanoprost, as well as Trabodenoson monotherapy that is in pre-clinical studies for the treatment of optic neuropathy and degenerative retinal diseases. The company was founded in 1999 and is headquartered in Lexington, Massachusetts.

Trade Information
Trade Type
LONG
ReliabilityScore™
92.75
Entry Date
Sep 20, 2017
Entry Price
1.41
Sell Date
Oct 16, 2017
Sell Price
2.41
Net Gain
71.27%
Hold Time
18 Trading Days